Product Description
Mechanisms of Action: PKC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: ST Elevation Myocardial Infarction|Myocardial Infarction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PROTECTION AMI | P2 |
Completed |
Myocardial Infarction |
2011-05-25 |
|
PROTECTION AMI | P2 |
Completed |
ST Elevation Myocardial Infarction |
2010-07-01 |
|
DELTA MI | P2 |
Completed |
ST Elevation Myocardial Infarction |
2006-11-28 |
|
KAI-9803-001 | P2 |
Completed |
ST Elevation Myocardial Infarction |
2006-10-01 |